Medicine
 |
|
6 april 2020 16:00:19 |
| NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension (BMC Pulmonary Medicine) |
|
Tweet NTP42 is a novel antagonist of the thromboxane prostanoid receptor (TP), currently in development for the treatment of pulmonary arterial hypertension (PAH). PAH is a devastating disease with multiple pathophysio... |
| 176 viewsCategory: Medicine |
 Perioperative Dexmedetomidine for outpatient cataract surgery: a systematic review (BMC Anesthesiology)Autoimmune pulmonary alveolar proteinosis developed during immunosuppressive treatment in polymyositis with interstitial lung disease: a case report (BMC Pulmonary Medicine) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
